Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) (NYSE: BDX) announced the launch of BD Horizon RealYellow™ 586 Reagents, a breakthrough in flow cytometry developed using novel dye technology and AI guidance. These reagents enable improved data resolution, facilitating deeper biological insights in oncology, autoimmune disorders, and infectious diseases. The reagents support both conventional and spectral flow cytometry, allowing researchers to analyze more markers per sample. With their global availability, BD aims to enhance research capabilities and accelerate drug development.

BD (Becton, Dickinson and Company) has established the Sustainable Medical Technology Institute to enhance its environmental sustainability efforts. This initiative targets three key areas: sustainable product design, sterilization technologies, and materials of concern. By leveraging interdisciplinary expertise, BD aims to reduce the environmental impact of its products while supporting its 2030+ environmental, social, and governance (ESG) commitments. The institute will collaborate globally and set environmental criteria for new products to better meet sustainability needs.

BD (Becton, Dickinson and Company) will report its financial results for the second quarter of fiscal year 2022 on May 5, 2022, at approximately 6:30 a.m. ET. The announcement will include summary financial information for the quarter ending March 31, 2022. Management will conduct a conference call at 8 a.m. ET on the same day to discuss results and operational strategy.

Investors can access the news release and presentation materials on the company’s investor relations website.

BD (Becton, Dickinson and Company) has successfully completed its spinoff of Embecta Corp, which now operates independently, focusing on diabetes care. Shareholders received one share of Embecta for every five shares of BD held as of March 22, 2022. This strategic move aligns with BD's 2025 plan to enhance long-term shareholder value by allowing both companies to concentrate on their core businesses. Embecta aims to further develop diabetes injection devices, while BD continues to lead in medical and life sciences sectors.

BD (Becton, Dickinson and Company) announced that Alberto Mas will retire as executive vice president and president of the Medical segment, effective September 30, 2022. Mas has served in various leadership roles at BD over nearly 30 years. The company is grateful for his contributions, as stated by CEO Tom Polen, and plans to appoint a successor before Mas's departure. BD continues to focus on advancing healthcare and enhancing the performance of its diverse medical technology solutions.

BD (Becton, Dickinson and Company) announced early results for Morgan Stanley's cash tender offers for specific notes, with a maximum purchase price of $200 million. As of March 29, 2022, holders had validly tendered approximately $1.6 billion in notes, exceeding the maximum limit, which led to a pro-rata acceptance of Floating Rate Notes due June 2022, totaling $199 million. Other notes tendered will not be accepted. The Offers are subject to specific conditions as detailed in the Offer to Purchase.

BD (Becton, Dickinson and Company) has announced key details regarding the spin-off of its diabetes care business, Embecta Corp.. Shareholders of BD as of March 22, 2022 will receive one share of Embecta for every five shares of BD held. 'When issued' trading of Embecta is set to commence on March 21, 2022, under ticker EMBCV, with 'regular way' trading starting on April 1, 2022 under EMBC. The transaction is expected to be tax-free. BD shareholders should consult tax advisers for implications of this spin-off.

BD (Becton, Dickinson and Company) announced that Morgan Stanley has initiated cash tender offers for various notes, totaling a maximum combined purchase price of $200,000,000. The offers include multiple series of notes with varying acceptance priority levels and offer details, including early tender premiums. The offers are scheduled to expire on April 12, 2022, with an early tender date of March 29, 2022. Holders of the notes must tender by these deadlines to receive maximum consideration. The company emphasizes the offers' conditions based on the successful completion of a financing transaction.